Ennature Biopharma has announced the results of its recently concluded Joint Health clinical study on its proprietary curcumin ingredient, Maxicuma®. This study is the final part of the clinical package, which evolved from its published Pharmacokinetic study in healthy human subjects, where the superior bioavailability was proven against standardised curcumin extract of 95%.
“This clinical research is pivotal, as it correlates the superior bioavailability to the higher efficacy of the ingredient in a robust study. Further the dosing options of 100 mg and 250 mg, gives a greater flexibility to the formulators in the Joint health and active nutrition space, as never before” said Akshay Bansal, the Global Business Head of the company.
Study Details:
The randomized, double-blind, placebo-controlled study included 180 subjects of either sex aged between 45 and 65, with mild to moderate Osteoarthritis. The study includes three arms (n =60 each) with 12-week supplementation, where the participants were administered either a placebo or Maxicuma® at a strength of 100mg or 250mg, respectively.
The participants were accessed at periodic intervals, on Day 0, 30, 45, 60 and 90 respectively, for Joint pain, Joint functions and physical activity using validated scales like Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) and Visual Analog Scale (VAS), along with the objective assessment of physical performance by treadmill walk test.
The participants from both the active groups, have reported statistically significant reduction in Joint pain and improvement in other efficacy variables like Joint stiffness, mobility, etc, from day 30 onwards against the placebo group. Within the active groups, Maxicuma® 250mg have shown statistically significant difference against Maxicuma® 100mg from day 45 onwards until the study completion.
To learn more write us at ennature@indiaglycols.com or visit our website https://www.ennaturebiopharma.com/
